News
美国马萨诸塞州剑桥（Cambridge, MA），2024年01月03日——APRINOIA Therapeutics Inc.（“APRINOIA”或本“公司”）很高兴地宣布，公司收到美国食品药品监督管理局 (“FDA”) 于2023年12月08日发出的“临床试验批准通知书” (“Study May Proceed” Letter)，针对APRINOIA新提交的研究性新药申请--关于18F-APN-1607 (INN：florzolotau (18F)) (“APN-1607”) 正电子发射断层扫描 (“PET”)在疑似罹患进行性核上性麻痹(“PSP”)病人中进行诊断功...
该投资支持新旭生技将精准医疗引入神经科学、推进公司的诊断和治疗管线的卓越努力 资金支持新旭生技将一项中枢神经系统（CNS）蛋白降解剂候选药物计划推入新药临床试验申请（IND）的目标 所得款项还将推进新旭生技后期阶段的tau PET示踪剂应用在进行性核上性麻痹（PSP）诊断的全球单一关键性三期临床试验 美国马萨诸塞州剑桥，2023年9月11日--总部位于美国马萨诸塞州剑桥、并以针对神经退行性疾病开发创新精准诊断及...
作为制药及生物技术领域的科研及决策高管，Shearman博士在药物发现和开发具备丰富经验且成绩斐然。他将领导公司临床治疗和诊断项目的战略和执行，为公司发展和增长做出贡献 波士顿2023年8月28日 11:00:00ET--新旭生技（简称“新旭”）是一家全球型临床阶段的生物制药公司，针对包括阿尔茨海默病（“AD”）、帕金森病（“PD”）以及某些罕见痴呆症和运动失调等神经退行性疾病积极开发新颖疗法和精准诊断技术，于今（28）日宣布，董...
BOSTON, April 11, 2022 -- APRINOIA Therapeutics announces today that the U.S. Food and Drug Administration (FDA) has granted a may proceed authorization for its novel therapeutic anti-tau monoclonal antibody, APNmAb005, allowing the company to test and evaluate its safety in healthy subjects in a phase 1 single ascending dose study. APNmAb005 is a unique antibody that recognizes a ...
APRINOIA Therapeutics has completed Series C financing with a total amount of $40 million USD in 2021. The financing was led by Yantai Dongcheng Pharmaceutical Group and syndicated by current shareholders KTB Network, IMM, and TaiAn Technologies and several new investors, including Harvest Capital, a fund established by the Management Committee of Suzhou Industrial Park (SIP). The new fun...
TAIPEI, Taiwan, Dec. 30, 2020 /PRNewswire/ -- Insilico Medicine is pleased to announce that it has entered into a research collaboration with APRINOIA Therapeutics to utilize Insilico's novel generative artificial intelligence (AI) technology to accelerate the discovery of next generation compounds targeting abnormal proteins in brain associated with neurodegenerative ...
APRINOIA Therapeutics Inc. today announced that they had executed a worldwide non-exclusive licensing agreement for Biogen Inc. (Nasdaq: BIIB) to access APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, for neurodegenerative diseases. This is an extension of a collaboration between APRINOIA and Biogen to discover novel PET imaging tracers for visualization and quantifi...
Suzhou, China- October 28, 2020- APRINOIA Therapeutics announced today that China National Medical Products Administration (NMPA) had approved to initiate Phase 3 clinical trial to evaluate APRINOIA’s positron emission tomography (PET) imaging tracer, 18F-APN-1607, targeting abnormal tau protein aggregates in brains of patients of cognitive impairment. 18F-APN-1607 is a new generation tau PET ...
APRINOIA Therapeutics, Inc. announced today that it has initiated a Phase 2 multicenter, multinational study of F-APN-1607 in the US for its lead tau positron emission tomography (PET) tracer in Alzheimer's Disease (AD). The study (NCT number: NCT04141150) will compare tau deposition patterns in patients with mild cognitive impairment due to AD and dementia due to AD with patterns ...
